Danuglipron Research

West L, Patolia H, Chapman B, Laffin L, Vest AR, Sauer AJ et al.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for glycemic control in type 2 diabetes, have emerged as transformative agents with broad therapeutic applications across multiple organ systems. This review explores the expanding role of GLP-1 RAs in managing cardiometa...

Kanapeckaitė A, Okuyan S, Wagg DJ, Koster J, Jančorienė L, Sakalauskaitė I et al.

Therapeutic interventions for complex diseases depend on the targeted modulation of key pathological pathways. While growing clinical needs continue to drive advancements in the drug discovery space, current strategies primarily rely on searching large volumes of chemical data without addressing ...

Dosda A, Fauchier G, Sabbah N, Fauchier L, Lecomte T, Ducluzeau PH et al.

To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP1-RA) use and all-cause mortality in patients with type 2 diabetes treated for colorectal cancer, using a real-world health database.This retrospective cohort study was conducted using the TriNetX global health recor...

Nauck MA, Tuttle KR, Tschöp MH, Blüher M

GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce ris...

Bhattarai HB, Paudel BS, Parajuli SR, Dahal K, Shah S, Bhattarai M et al.

Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller ...

Zhou J, Wang F, Li S

This study assesses the efficacy and safety of the novel oral small molecule glucagon-like peptide-1 receptor agonists (GLP-1 RAs) danuglipron and orforglipron in the treatment of type 2 diabetes (T2DM) and obesity through systematic review and meta-analysis.Electronic databases (PubMed, Web of S...

Kahn SE, Tripputi M, Lachin JM, Balasubramanyam A, Banerji MA, Barzilay J et al.

To determine the longitudinal effects on α-cell function of four classes of glucose-lowering agents added to metformin in adults with type 2 diabetes.In a multicenter, randomized study, 5,047 participants ≥30 years of age with type 2 diabetes taking 1,000-2,000 mg metformin daily, Hb...

Lehenbauer KS, Nelson AJ, Nodari S, Sverdlov AL, Harrington J

Subcutaneous glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce risk of major adverse cardiac events (MACE) for patients with type 2 diabetes (T2DM) who have or are at high risk of cardiovascular disease, but the evaluation of cardiovascular efficacy of oral GLP-1 RAs...

Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG et al.

Obesity is a chronic disease that significantly contributes to type 2 diabetes and its complications. We aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes.This 72-week, phase 3, double-blind, placebo-c...

Bultinck J, Yuan S, Cantuti-Castelvetri L, Brosens L, Bracke D, Collins J et al.

The NLRP3 inflammasome is a key innate immune sensor that orchestrates inflammatory responses to diverse stress signals, including metabolic danger cues. Dysregulated NLRP3 activation has been implicated in chronic diseases such as type 2 diabetes, atherosclerosis, and neurodegeneration, undersco...

Badulescu S, Gill H, Shah H, Brudner R, Phan L, Di Vincenzo JD et al.

Evidence suggests that glucagon-like peptide 1 receptor agonists (GLP-1RAs) might have pro-cognitive effects. No prior study has evaluated the efficacy and safety of a GLP-1RA for the treatment of cognitive dysfunction in adults with major depressive disorder (MDD) in a randomized clinical trial....

GBD 2023 Disease and Injury and Risk Factor Collaborators

For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable heal...

Son JW, le Roux CW, Blüher M, Nauck MA, Lim S

The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel GLP-1-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-enter...

Fredrick TW, Camilleri M, Acosta A

In this narrative review we describe the recent updates regarding anti-obesity medications as of February 2025. We describe the physiologic mechanisms underpinning the development of hunger, satiation, and maintenance of satiety to address targets for anti-obesity medications. The efficacy, mecha...

Toledo FGS, Li Y, Wang F, Bellin MD, Brand R, Cusi K et al.

Pancreatic ductal adenocarcinoma-related diabetes mellitus (PDAC-DM) is a paraneoplastic syndrome with a poorly understood pathophysiology. PDAC-DM is often clinically confused with type 2 diabetes, resulting in delayed cancer detection and poorly individualised hyperglycaemia treatment. We inves...

Tolkacheva EV, Saliev AY, Salakhov TL, Balakin KV, Ivanov RA, Chernyshov VV et al.

GLP-1 receptor peptide agonists have revolutionized type 2 diabetes mellitus and obesity treatment, primarily through injection-based therapies. Small-molecule GLP-1 receptor agonists allow oral administration, but none are clinically established. Pfizer's danuglipron and lotiglipron, presented i...

Jaiswal A, Biradar R, Deshmukh V, Deshpande R, Nandi S

Small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists are emerging as promising therapeutic agents for type 2 diabetes mellitus (T2DM) and obesity. Danuglipron, a novel investigational GLP-1R agonist, has demonstrated notable efficacy in clinical trials. This study aimed to evaluate t...

Dailey KA, Schneider LN, Petreaca RC, Yoder RJ

The targeting of the G-protein coupled receptor (GPCRs) glucagon-like-peptide-1-receptor (GLP-1R) by weight loss medications has become extremely prevalent due to the effectiveness of a class of GLP-1R agonists. Also, interest in cannabinoids, such as delta-9-tetrahydrocannabinol (THC), has risen...

Xu M, Vogel H, Yuan S

The glucagon-like peptide-1 receptor (GLP-1R), which belongs to the class B1 G protein-coupled receptor (GPCR) family, is an important target for treatment of metabolic disorders, including type 2 diabetes and obesity. The growing interest in GLP-1R-based therapies is driven by the development of...

Malik RA, Anderson J, Russo G, Amani MEA, Adaş M, Alvarez A et al.

To evaluate the effectiveness and safety of a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) over 24 months in people with type 2 diabetes (T2D).In this retrospective, observational study, data were collected from the Optum Market Clarity® dat...